# ALCOHOL CUE HUMAN LABORATORY STUDY TESTING ASP 8062

> **NIH NIH N01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $282,458

## Abstract

The primary objective of this study is to evaluate the effects of ASP8062, 25 mg once a day and matched placebo, on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 2 weeks of daily dosing among subjects with moderate to severe alcohol use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5™). Secondary objectives include evaluation of ASP8062, 25 mg once a day, and matched placebo on reduction of alcohol consumption, alcohol craving, cigarette smoking (among smokers) and nicotine use (among nicotine users), mood, sleep, alcohol use negative consequences, study retention, and safety and tolerability throughout the last 4 weeks of the treatment phase of the study.

## Key facts

- **NIH application ID:** 10953468
- **Project number:** 75N94021D00008-P00002-759402100002-2
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** LARA RAY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $282,458
- **Award type:** —
- **Project period:** 2021-09-17 → 2023-09-16

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10953468

## Citation

> US National Institutes of Health, RePORTER application 10953468, ALCOHOL CUE HUMAN LABORATORY STUDY TESTING ASP 8062 (75N94021D00008-P00002-759402100002-2). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10953468. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*